Antiangiogenic approach in soft-tissue sarcomas

References

• van Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line egimens – a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J. Clin. Oncol. 17(1), 150–157 (1999).
   PubMed Web of Science ®Google Scholar
• van Oosterom AT, Mouridsen HT, Nielsen OS et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur. J. Cancer 38(18), 2397–2406 (2002).
   PubMed Web of Science ®Google Scholar
• Italiano A, Mathoulin-Pelissier S, Le Cesne A et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 117(5), 1049–1054 (2011).
   PubMed Web of Science ®Google Scholar
• Leahy M, Garcia Del Muro X, Reichardt P et al. Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. TheSArcoma treatment and Burden of Illness in North America and Europe (SABINE) study. Ann. Oncol. 23(10), 2763–2770 (2012).
   PubMed Web of Science ®Google Scholar
• van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet 379(9829), 1879–1886 (2012).
   PubMed Web of Science ®Google Scholar
• Chawla SP, Blay JY, Ray-Coquard IL et al. Results of the Phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J. Clin. Oncol. 29(Suppl.), Abstract 10005 (2011).
   PubMed Web of Science ®Google Scholar
• Escudier B, Kataja V; ESMO Guidelines Working Group. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20(Suppl. 4), 81–82 (2009).
   PubMed Web of Science ®Google Scholar
• Potti A, Ganti AK, Tendulkar K et al. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J. Cancer Res. Clin. Oncol. 130(1), 52–56 (2004).
   PubMed Web of Science ®Google Scholar
• Graeven U, Andre N, Achilles E et al. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor inpatients with soft-tissue sarcoma. J. Cancer Res. Clin. Oncol. 125(10), 577–581 (1999).
   PubMed Web of Science ®Google Scholar
• Hayes AJ, Mostyn-Jones A, Koban MU et al. Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br. J. Surg. 91(2), 242–247 (2004).
   PubMed Web of Science ®Google Scholar
• Chao C, Al-Saleem T, Brooks JJ et al. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann. Surg. Oncol. 8(3), 260–267 (2001).
   PubMed Web of Science ®Google Scholar
• Iyoda A, Hiroshima K, Baba M et al. Expression of vascular endothelial growth factor in thoracic sarcomas. Ann. Thorac. Surg. 71(5), 1635–1639 (2001).
   PubMedGoogle Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25(4), 581–611 (2004).
   PubMed Web of Science ®Google Scholar
• Kilvaer TK, Valkov A, Sorbye S et al. Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis. PLoS One 5(12), e15368 (2010).
   PubMedGoogle Scholar
• Shintani K, Matsumine A, Kusuzaki K et al. Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas. Virchows. Arch. 449(6), 673–681 (2006).
   PubMed Web of Science ®Google Scholar
• D'Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J. Clin. Oncol. 23(28), 7135–7142 (2005).
   PubMed Web of Science ®Google Scholar
• Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25, 1753–1759 (2007).
   PubMed Web of Science ®Google Scholar
• Constantinidou A, Jones RL, Olmos D et al. Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour. Acta. Oncol. 51(4), 550–554 (2012).
   PubMed Web of Science ®Google Scholar
• Park MS, Patel SR, Ludwig JA et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer 117(21), 4939–4947 (2011).
   PubMed Web of Science ®Google Scholar
• Verschraegen CF, Arias-Pulido H, Lee SJ et al. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann. Oncol. 23(3), 785–790 (2012).
   PubMed Web of Science ®Google Scholar
• Yoon SS, Duda DG, Karl DL et al. Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 81(4), 1081–1090 (2011).
   PubMed Web of Science ®Google Scholar
• George S, Merriam P, Maki RG et al. Multicenter Phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J. Clin. Oncol. 27(19), 3154–3160 (2009).
   PubMed Web of Science ®Google Scholar
• Tariq Mahmood S, Agresta S, Vigil CE et al. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int. J. Cancer 129(8), 1963–1969 (2011).
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Negri T, Zaffaroni N et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann. Oncol. 22(7), 1682–1690 (2011).
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Negri T, Libertini M et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann. Oncol. 23(12), 3171–3179 (2012).
   PubMed Web of Science ®Google Scholar
• Hensley ML, Sill MW, Scribner DR Jr et al. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group Phase II study. Gynecol. Oncol. 115(3), 460–465 (2009).
   PubMed Web of Science ®Google Scholar
• Maki RG, D’Adamo DR, Keohan ML et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J. Clin. Oncol. 27(19), 3133–3140 (2009).
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Italiano A, Bompas E et al. Sorafenib for patients with advanced angiosarcoma: a Phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist 17(2), 260–266 (2012).
   PubMed Web of Science ®Google Scholar
• Von Mehren M, Rankin C, Goldblum JR et al. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 118, 770–776 (2012).
   PubMed Web of Science ®Google Scholar
• Pacey S, Ratain MJ, Flaherty KT et al. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Investig. New Drugs 29(3), 481–488 (2011).
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Silletta M, Schiavon G et al. Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience. Expert Opin. Investig. Drugs 22(1), 1–7 (2013).
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a Phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J. Clin. Oncol. 27(19), 3126–3132 (2009).
   PubMed Web of Science ®Google Scholar
• D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91(9), 4082–4085 (1994).
   PubMed Web of Science ®Google Scholar
• Yi-Shin Kuo D, Timmins P, Blank SV et al. Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium. Gynecol. Oncol. 100(1), 160–165 (2006).
   PubMedGoogle Scholar
• McMeekin DS, Sill MW, Darcy KM et al. A Phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol. Oncol. 106(3), 596–603 (2007).
   PubMed Web of Science ®Google Scholar
• Boyar MS, Hesdorffer M, Keohan ML et al. Phase ii study of temozolomide and thalidomide in patients with unresectable or metastatic leiomyosarcoma. Sarcoma 2008, 412503 (2008).
   PubMedGoogle Scholar
• Belotti D, Vergani V, Drudis T et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2, 1843–1849 (1996).
   PubMed Web of Science ®Google Scholar
• Fata F, O’Reilly E, Ilson D et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86(10), 2034–2037 (1999).
   PubMed Web of Science ®Google Scholar
• Schlemmer M, Reichardt P, Verweij J et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer 44(16), 2433–2436 (2008).
   PubMed Web of Science ®Google Scholar
• Penel N, Bui BN, Bay JO et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J. Clin. Oncol. 26(32), 5269–5274 (2008).
   PubMed Web of Science ®Google Scholar
• Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 104(2), 361–366 (2005).
   PubMed Web of Science ®Google Scholar
• Italiano A, Cioffi A, Penel N et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer 118(13), 3330–3336 (2012).
   PubMed Web of Science ®Google Scholar
• Penel N, Italiano A, Ray-Coquard I et al. Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Ann. Oncol. 23(2), 517–523 (2012).
   PubMed Web of Science ®Google Scholar
• Kim SY, Kim DH, Lee HJ et al. Treatment of disseminated classic type of kaposi's sarcoma with paclitaxel. Ann. Dermatol. 23(4), 504–507 (2011).
   PubMed Web of Science ®Google Scholar
• Silvestris N, Galetta D, Colucci G. Successful treatment with three-weekly paclitaxel of an anthracycline-refractory classical Kaposi's sarcoma. Anticancer Res. 29(2), 675–676 (2009).
   PubMedGoogle Scholar
• Ardavanis A, Doufexis D, Kountourakis P, Rigatos G. A Kaposi's sarcoma complete clinical response after sorafenib administration. Ann. Oncol. 19(9), 1658–1659 (2008).
   PubMed Web of Science ®Google Scholar
• Brambilla L, Romanelli A, Bellinvia M et al. Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases. Br. J. Dermatol. 158(6), 1339–1344 (2008).
   PubMed Web of Science ®Google Scholar
• Salech F, Valderrama S, Nervi B et al. Thalidomide for the treatment of metastatic hepatic epithelioid hemangioendothelioma: a case report with a long term follow-up. Ann. Hepatol. 10(1), 99–102 (2011).
   PubMedGoogle Scholar
• Mascarenhas RC, Sanghvi AN, Friedlander L et al. Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma. Oncology 67(5–6), 471–475 (2004).
   PubMedGoogle Scholar
• Maruwge W, D'Arcy P, Folin A et al. Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling. Onco Targets Ther. 1, 67–78 (2008).
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Cheema HS, Seelman S et al. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol. Cancer Ther. 7(4), 890–896 (2008).
   PubMed Web of Science ®Google Scholar
• Peng CL, Guo W, Ji T et al. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biol. Ther. 8(18), 1729–1736 (2009).
   PubMed Web of Science ®Google Scholar
• Shor AC, Keschman EA, Lee FY et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res. 67(6), 2800–2808 (2007).
   PubMed Web of Science ®Google Scholar
• Timeus F, Crescenzio N, Fandi A et al. In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines. Oncol. Rep. 19(2), 353–359 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang L, Hannay JA, Liu J et al. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Res. 66, 8770–8778 (2006).
   PubMed Web of Science ®Google Scholar
• Dias S, Shmelkov SV, Lam G, Rafii S. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 99, 2532–2540 (2002).
   PubMed Web of Science ®Google Scholar
• Tran J, Master Z, Yu JL et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl Acad. Sci. USA 99, 4349–4354 (2002).
   PubMed Web of Science ®Google Scholar
• Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure – an obstacle in cancer therapy. Nat. Rev. Cancer 4, 806–813 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia del Muro X, Lopez-Pousa A, Martin Broto J et al. Phase I study of sorafenib plus ifosfamide in patients with advanced soft tissue and bone sarcoma: a Spanish Group for Research on Sarcomas (GEIS) study. J. Clin. Oncol. 28, 15(Suppl.), Abstract 10024 (2010).
   Google Scholar
• Hamberg P, Boers-Sonderen M, Loos WJ et al. Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs). J. Clin. Oncol. 30(Suppl.), Abstract 2593 (2012).
   Google Scholar
• Van Glabbeke M, Verweij J, Judson I et al. Progression-free rate as the principal end-point for Phase II trials in soft-tissue sarcomas. Eur. J. Cancer 38(4), 543–549 (2002).
   PubMed Web of Science ®Google Scholar